Skip to main content

Table 1 Patients and tumor characteristics of the h-R3/RT and CDDP/RT groups (N = 104)

From: A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

  h-R3/RT (N = 52) CDDP/RT (N = 52)  
Characteristics [n (%)] [n (%)] P Value*
Age    1.000
  < 60 45 (86.5%) 45 (86.5%)  
60 7 (13.5%) 7 (13.5%)  
Sex    0.083
 Male 42 (82.7%) 36 (69.2%)  
 Female 10 (17.3%) 16 (30.8%)  
T category    0.799
 1 11 (21.2%) 11 (21.2%)  
 2 13 (25.0%) 14 (26.9%)  
 3 12 (23.1%) 12 (23.1%)  
 4 16 (30.7%) 15 (28.8%)  
N category    0.957
 0 3 (5.8%) 4 (7.7%)  
 1 20 (38.4%) 19 (36.5%)  
 2 23 (44.3%) 23 (44.3%)  
 3 6 (11.5%) 6 (11.5%)  
M category    1.000
 0 52 (100%) 52 (100%)  
 1 0 (0.00%) 0 (0.00%)  
Clinical stage    0.831
 II 13 (25.0%) 13 (25.0%)  
 III 20 (38.5 0%) 21 (40.4%)  
 IV (non-metastatic) 19 (36.5.0%) 18 (34.6%)  
Histologic type
 non-keratinizing 52 (100%) 52 (100%)  
 Total RT (70/74)a (70/74)a  
dose (Gy)
 ECOG 0-2 0-2  
  1. Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy. ECOG Eastern Cooperative Oncology Group
  2. aa total of 74 Gy when patients had skull base bone destruction
  3. *All p values were obtained by the non-parametric test